BAP31 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin, a member of the statin class, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the mevalonate pathway. By blocking cholesterol biosynthesis, it indirectly influences BAP31 expression and function, as BAP31 is involved in cholesterol trafficking within the endoplasmic reticulum. Lovastatin's action alters the lipid composition, impacting cellular processes associated with BAP31 regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks), affecting the PI3K/AKT signaling pathway. BAP31 interacts with components of the AKT pathway, and Wortmannin's inhibition of PI3K indirectly modulates BAP31 by disrupting downstream signaling. The altered phosphorylation cascades and intracellular dynamics can lead to changes in BAP31 localization and function within the endoplasmic reticulum, affecting protein trafficking and ER stress responses. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1). BAP31 undergoes glycosylation, and Tunicamycin disrupts this process, influencing BAP31 maturation and its interactions with other proteins. This disturbance in post-translational modification can impact the stability and function of BAP31 within the ER membrane. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose is a glucose analog that competitively inhibits glucose metabolism. BAP31 is involved in energy sensing and ER stress responses. By disrupting glucose metabolism, 2-Deoxy-D-glucose indirectly affects BAP31's role in cellular responses to nutrient availability and ER stress. This altered metabolic state can lead to modifications in BAP31 function, influencing its participation in cellular processes related to apoptosis and autophagy. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A inhibits ADP-ribosylation factor (ARF) and disrupts protein trafficking between the endoplasmic reticulum (ER) and Golgi apparatus. BAP31 is a key player in ER-Golgi transport. Brefeldin A's interference with this process indirectly affects BAP31 by altering its localization and disrupting its involvement in vesicular transport. The resulting changes in ER homeostasis can impact BAP31-mediated protein sorting and export from the ER. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is an inhibitor of heat shock protein 90 (Hsp90), a chaperone protein involved in protein folding and stability. BAP31 interacts with Hsp90, and 17-AAG disrupts this interaction, leading to destabilization of BAP31. This destabilization affects BAP31's involvement in quality control mechanisms within the ER, leading to altered cellular responses to unfolded proteins and influencing the ER-associated degradation (ERAD) pathway. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
BML-275 (Dorsomorphin) is a selective inhibitor of AMP-activated protein kinase (AMPK). BAP31 is implicated in cellular responses to energy stress. Dorsomorphin's inhibition of AMPK indirectly modulates BAP31 by altering energy-sensing pathways. The resulting changes in AMPK activity can influence BAP31-mediated responses to metabolic stress and ER homeostasis, impacting cellular processes related to autophagy and apoptosis. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an inhibitor of Akt, a kinase involved in the PI3K/AKT signaling pathway. BAP31 interacts with components of the AKT pathway, and Perifosine's inhibition of Akt indirectly modulates BAP31 by disrupting downstream signaling. The altered phosphorylation cascades and intracellular dynamics can lead to changes in BAP31 localization and function within the endoplasmic reticulum, affecting protein trafficking and ER stress responses. | ||||||
4-Phenylbutyric acid | 1821-12-1 | sc-232961 sc-232961A sc-232961B | 25 g 100 g 500 g | $53.00 $136.00 $418.00 | 10 | |
4-Phenylbutyric acid (4-PBA) is a chemical chaperone that assists in protein folding and trafficking. BAP31 plays a role in ER-associated degradation (ERAD). 4-PBA indirectly influences BAP31 by promoting proper folding of misfolded proteins, reducing the load on ERAD pathways. This chaperone activity can impact BAP31's involvement in quality control mechanisms within the ER, influencing cellular responses to unfolded proteins and protein degradation processes. | ||||||
GSK 2606414 | 1337531-36-8 | sc-490182 sc-490182A | 5 mg 25 mg | $163.00 $572.00 | ||
GSK2606414 is a selective inhibitor of protein kinase R-like endoplasmic reticulum kinase (PERK), a key regulator of the unfolded protein response (UPR). BAP31 is involved in UPR signaling. GSK2606414's inhibition of PERK indirectly modulates BAP31 by altering UPR pathways. The resulting changes in PERK activity can influence BAP31-mediated responses to ER stress, affecting cellular processes related to apoptosis and protein quality control. | ||||||